<qa>  How many subjects with soft tissue sarcoma will be enrolled in the dose levelIf there is an effective case in a given dose level and the safety is good There is no more than Grade 2 adverse event not included Grade 2, 6-14 subjects with soft tissue sarcoma will be enrolled in the dose level as expanded cohort. The subjects of expanded cohort will use repeated doses every 2 weeks like multiple dose cohorts to further evaluate safety and efficacy of JS-001 with soft tissue sarcoma. At the same time, 9-12 subjects with hodgkin lymphoma will be enrolled in 3 mgkgdose level as expanded cohort. The subjects of expanded cohort will use repeated doses every 2 weeks like multiple dose cohorts to further evaluate safety and efficacy of JS-001 with hodgkin lymphoma. 